Cagrilintide: The Next-Gen Amylin Analog Explained

Cagrilintide is a long-acting amylin analog. Amylin is a peptide co-secreted with insulin from pancreatic beta cells, with effects on satiety and gastric emptying that are complementary to GLP-1.

Mechanism

Cagrilintide binds amylin and calcitonin receptors. The result in research models is reduced food intake and delayed gastric emptying — additive to GLP-1 effects.

CagriSema

"CagriSema" is the research pairing of cagrilintide with semaglutide. The combination has shown stronger weight-loss effects in trials than either alone.

Typical dosing

Weekly subcutaneous, 0.5–2.4 mg titrated similarly to semaglutide.

For the closest mainstream comparison see retatrutide vs tirzepatide.

Frequently asked questions

Is cagrilintide a GLP-1?

No — it is an amylin analog. Different receptor family.

Can it be paired with tirzepatide?

Limited research data. CagriSema (with semaglutide) is the studied pairing.

This guide is provided for informational purposes by Next Day Pharma. All peptides supplied are FOR RECONSTITUTION. Always consult a qualified healthcare professional before use.